Navigation Links
FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS
Date:11/30/2009

(sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU and GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in Phase I/II clinical development for the treatment of MPS IVA. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: the expectations of the development and potential approval of Huxley's 3,4-Diaminopyridine product for the treatment of LEMS. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities, particularly the pending decision by the European Commission on the Marketing Authorization Application for such product, our success in the commercialization of such product, if approved; results and timing of current and planned preclinical studies and clinical trials related to such product; our ability to successfully manufacture the product; and those factors detailed in BioMarin's filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption "Risk Factors" in BioMarin's 2008 Annual Report on Form 10-K, and the factors contained in BioMarin's reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-lo
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Mirus Bio Awarded Grants & Contracts of Over $5 Million
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
4. NIH grants $750,000 to develop device to determine temperature of neonates brain
5. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
6. Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis
7. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
8. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
9. NASDAQ Panel Grants Merge Technologies Additional Time to Regain Compliance
10. FDA Grants Resverlogix Approval to Commence a Phase 1 Clinical Trial for RVX-208
11. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Rice University scientists who created a deicing film for ... as a transparent coating for glass. , The ... colleagues could keep glass surfaces from windshields to skyscrapers ... to radio frequencies (RF). , The technology was ... Applied Materials and Interfaces . , The ...
(Date:9/16/2014)... Cardioxyl Pharmaceuticals, Inc. announced today ... to be effective in animal models following oral (capsule) ... infusions that could pave the way for convenient outpatient ... at the Heart Failure Society of America,s (HFSA) 18 ... Vegas . The research, conducted in ...
(Date:9/16/2014)... 2014 CIRTEC Medical Systems’ Board of ... CEO of CIRTEC. , “I am delighted to ... Company.” noted Brian Highley. “The company has made great ... organic growth over the past two years. The goal ... improve and expand the services Cirtec offers its medical ...
(Date:9/16/2014)... 16, 2014   Synthetic Biologics, Inc. ... anti-infective biologic and drug programs targeting specific pathogens ... completion of the Company,s Investor Day in ... irritable bowel syndrome (IBS) program, including its novel, ... In the keynote presentation, Mark Pimentel ...
Breaking Biology Technology:Nanoribbon film keeps glass ice-free 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 2Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day 3
... CHERRY HILL, N.J., Sept. 21 Nuvilex, Inc. (OTC Bulletin ... venture partner with Reme-Flu(TM), will be incorporating Syn-X9(TM) proprietary delivery ... remedy designed to help prevent and treat flu-type symptoms resulting ... , , The unique attributes ...
... Merrimack Pharmaceuticals, Inc., announced today that Clet Niyikiza, Ph.D., ... Niyikiza comes to Merrimack from GlaxoSmithKline (GSK) where he was ... Niyikiza has extensive drug development experience with a career ... which he has led ten New Drug Application teams that ...
... , , ROCKVILLE, Md., Sept. 21 ... the U.S. Food and Drug Administration (FDA) has approved its Investigational New ... Lateral Sclerosis (ALS or Lou Gehrig,s disease) with its spinal cord stem ... ) , , Neuralstem is the first ...
Cached Biology Technology:Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 2Nuvilex, Inc. Announced that Reme-Flu(TM) will Incorporate Proprietary Syn-X9(TM) Delivery Technology into its Product Formulation 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 2Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 3Neuralstem Receives FDA Approval to Commence First ALS Stem Cell Trial 4
(Date:9/16/2014)... inherit certain traits from our parents that are pre-determined. ... play out by taking certain drugs or better yet, ... team of researchers at the Boston University School of ... research. , Epigenetics regulates gene expression in a ... which prevent permanent mutations or alterations within the gene ...
(Date:9/16/2014)... Each tree species has its own bacterial identity. That,s ... from other institutions who studied the genetic fingerprints of ... Panamanian island. , "This study demonstrates for the first ... with different ecological strategies possess very different microbial communities ... a former postdoctoral researcher in the UO,s Institute of ...
(Date:9/16/2014)... a 10-km diameter chunk of rock hit the Yukatan peninsula ... the force of 100 teratons of TNT. It left a ... wildfires, global earthquakes and volcanism are widely accepted to have ... of the mammals. But what happened to the plants on ... researchers from the University of Arizona reveals that the meteorite ...
Breaking Biology News(10 mins):Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 2Epigenetic drugs: A hope to treat cancer resistance and reduce cancer relapse? 3Microbiome research shows each tree species has a unique bacterial identity 2Meteorite that doomed the dinosaurs helped the forests bloom 2Meteorite that doomed the dinosaurs helped the forests bloom 3
... a sudden halt, the carbon dioxide already in Earth,s atmosphere ... according to Princeton University-led research published in the journal ... take a lot less carbon than previously thought to reach ... an Earth on which, after 1,800 billion tons of carbon ...
... Think Greenland,s ice sheet is small today? It was ... history from 3-5,000 years ago, according to scientists who studied ... interpreting the Arctic fossil record. "What,s really interesting about this ... 5,000 years ago, maybe as late as 4,000 years ago. The ...
... Gregg, an assistant professor of mechanical engineering and bioengineering ... Computer Science this fall, is a recipient of a ... for research that will combine robot control theory and ... orthotic devices. "According to the American Society of ...
Cached Biology News:Even if emissions stop, carbon dioxide could warm Earth for centuries 2Even if emissions stop, carbon dioxide could warm Earth for centuries 3Greenland's shrunken ice sheet: We've been here before 2Greenland's shrunken ice sheet: We've been here before 3UT Dallas professor wins $2.3 million NIH award 2UT Dallas professor wins $2.3 million NIH award 3
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
... freezers offer a superior sample management ... samples with high capacities. Innovative insulation ... ensure excellent warming protection and ensure ... accessories simplify tracking of sample location ...
...
Verotoxin IIbeta (457)...
Biology Products: